Bladder Cancer-Pipeline Review, H2 2015

Bladder Cancer-Pipeline Review, H2 2015

  • Products Id :- GMDHC6939IDB
  • |
  • Pages: 508
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Bladder Cancer-Pipeline Review, H2 2015


Global Markets Direct's, 'Bladder Cancer-Pipeline Review, H2 2015', provides an overview of the Bladder Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bladder Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bladder Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Bladder Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Bladder Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Bladder Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Bladder Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 11

Introduction 12

Global Markets Direct Report Coverage 12

Bladder Cancer Overview 13

Therapeutics Development 14

Pipeline Products for Bladder Cancer-Overview 14

Pipeline Products for Bladder Cancer-Comparative Analysis 15

Bladder Cancer-Therapeutics under Development by Companies 16

Bladder Cancer-Therapeutics under Investigation by Universities/Institutes 24

Bladder Cancer-Pipeline Products Glance 26

Late Stage Products 26

Clinical Stage Products 27

Early Stage Products 28

Bladder Cancer-Products under Development by Companies 29

Bladder Cancer-Products under Investigation by Universities/Institutes 37

Bladder Cancer-Companies Involved in Therapeutics Development 38

Advaxis, Inc. 38

Alligator Bioscience AB 39

Alnylam Pharmaceuticals, Inc. 40

Altor BioScience Corporation 41

AndroScience Corporation 42

APIM Therapeutics AS 43

Arno Therapeutics, Inc. 44

Ascenta Therapeutics, Inc. 45

Astellas Pharma Inc. 46

AstraZeneca Plc 47

AuraSense Therapeutics, LLC 48

AVEO Pharmaceuticals, Inc. 49

AvidBiotics Corp. 50

Bavarian Nordic A/S 51

Bayer AG 52

BioCancell Ltd 53

Bioncotech Therapeutics S.L. 54

Biotest AG 55

cCAM Biotherapeutics Ltd. 56

Celgene Corporation 57

Celldex Therapeutics, Inc. 58

Cold Genesys, Inc. 59

Daiichi Sankyo Company, Limited 60

DormaTarg, Inc. 61

Eisai Co., Ltd. 62

Eli Lilly and Company 63

EntreChem, S.L. 64

Esperance Pharmaceuticals, Inc. 65

Evotec AG 66

F. Hoffmann-La Roche Ltd. 67

Gene Signal International SA 68

Genmab A/S 69

GlaxoSmithKline Plc 70

Heat Biologics, Inc. 71

Horizon Pharma Plc 72

Hutchison MediPharma Limited 73

Idera Pharmaceuticals, Inc. 74

Immunomedics, Inc. 75

Immupharma Plc 76

ImmuRx, Inc. 77

Ludwig Institute For Cancer Research Ltd 78

MacroGenics, Inc. 79

Marina Biotech, Inc. 80

Meabco A/S 81

MedImmune, LLC 82

Merck & Co., Inc. 83

Millennium Pharmaceuticals, Inc. 84

Mirati Therapeutics Inc. 85

NuCana BioMed Limited 86

Omeros Corporation 87

Oncogenex Pharmaceuticals, Inc. 88

Oncolytics Biotech Inc. 89

Oncopeptides AB 90

Ono Pharmaceutical Co., Ltd. 91

Optimum Therapeutics, LLC 92

Panacela Labs, Inc. 93

Pfizer Inc. 94

Pharma Mar, S.A. 95

Polaris Pharmaceuticals, Inc. 96

PsiOxus Therapeutics Limited 97

Qu Biologics Inc. 98

Quest PharmaTech Inc. 99

Samyang Holdings Corporation 100

Sanofi 101

Serometrix, LLC 102

Shionogi & Co., Ltd. 103

Sorrento Therapeutics, Inc. 104

Spectrum Pharmaceuticals, Inc. 105

Stemline Therapeutics, Inc. 106

Sumitomo Dainippon Pharma Co., Ltd. 107

Sun Pharma Advanced Research Company Ltd. 108

Synta Pharmaceuticals Corp. 109

TARIS BioMedical, Inc. 110

Telesta Therapeutics Inc. 111

Telormedix SA 112

Theravectys SA 113

TheRyte Limited 114

Tolero Pharmaceuticals, Inc. 115

Transgene SA 116

Vakzine Projekt Management GmbH 117

Vaxeal Holding SA 118

Viralytics Ltd. 119

Viventia Biotechnologies Inc. 120

Bladder Cancer-Therapeutics Assessment 121

Assessment by Monotherapy Products 121

Assessment by Combination Products 122

Assessment by Target 123

Assessment by Mechanism of Action 128

Assessment by Route of Administration 132

Assessment by Molecule Type 134

Drug Profiles 136

ACP-196-Drug Profile 136

ADC-1013-Drug Profile 138

afuresertib hydrochloride + trametinib dimethyl sulfoxide-Drug Profile 140

aganirsen-Drug Profile 141

ALT-801-Drug Profile 143

ALT-803-Drug Profile 145

amrubicin hydrochloride-Drug Profile 147

Antibody to Inhibit TYRO-3 for Bladder Cancer-Drug Profile 149

Antisense Oligonucleotides for Bladder Cancer-Drug Profile 150

Antisense RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer-Drug Profile 151

apatorsen-Drug Profile 153

apaziquone-Drug Profile 155

APL-1202-Drug Profile 157

APTA-012-Drug Profile 158

AR-42-Drug Profile 159

ASC-JM.Z1-Drug Profile 161

ASG-15ME-Drug Profile 162

AST-008-Drug Profile 163

AT-406-Drug Profile 164

atezolizumab-Drug Profile 167

ATX-101-Drug Profile 171

AV-203-Drug Profile 172

AZD-4547-Drug Profile 173

AZD-5312-Drug Profile 175

B-701-Drug Profile 176

BAY-1163877-Drug Profile 177

BC-819-Drug Profile 178

Biologic for Superficial Bladder Cancer-Drug Profile 180

BO-110-Drug Profile 181

BPC-1-Drug Profile 182

BV-2711-Drug Profile 183

CDX-1401-Drug Profile 184

Cell Therapy for Bladder Cancer-Drug Profile 186

Cell Therapy to Target HER2 for Oncology-Drug Profile 187

CG-0070-Drug Profile 188

CM-24-Drug Profile 190

CV-301-Drug Profile 191

CVA-21-Drug Profile 193

DAB-389EGF-Drug Profile 197

Dendritic Cell Therapy to Target HER-2 for Oncology-Drug Profile 198

docetaxel-Drug Profile 199

Drug for NMIBC-Drug Profile 200

Drugs to Inhibit FGFR3 for Bladder Cancer-Drug Profile 201

Drugs to Inhibit TYRO-3 for Bladder Cancer-Drug Profile 202

dsP21-322-2'F-Drug Profile 203

DT-310-Drug Profile 204

DT-320-Drug Profile 205

DT-330-Drug Profile 207

durvalumab + tremelimumab-Drug Profile 208

EC-7072-Drug Profile 210

enadenotucirev-Drug Profile 211

enoblituzumab-Drug Profile 213

EP-400-Drug Profile 215

eribulin mesylate-Drug Profile 216

erlotinib hydrochloride-Drug Profile 221

GSK-2849330-Drug Profile 224

HMPL-453-Drug Profile 225

HuMax-TF-ADC-Drug Profile 226

ICT-2700-Drug Profile 228

imiquimod-Drug Profile 229

IMO-2055-Drug Profile 230

indatuximab ravtansine-Drug Profile 232

interferon gamma-1b-Drug Profile 234

IPP-204106-Drug Profile 237

JAAF-11-Drug Profile 239

lenalidomide-Drug Profile 240

Lm-LLO-ISG15-Drug Profile 245

lurbinectedin-Drug Profile 247

MDNA-55-Drug Profile 250

MDR-09521-Drug Profile 251

Melflufen-Drug Profile 252

mitomycin SR-Drug Profile 254

MMD-37K-Drug Profile 256

mocetinostat-Drug Profile 257

Monoclonal Antibodies to Inhibit VISTA for Bladder Cancer-Drug Profile 260

Monoclonal Antibody to Inhibit EGFR for Superficial Bladder Cancer-Drug Profile 261

MVAME-03-Drug Profile 262

MVXONCO-1-Drug Profile 263

nivolumab-Drug Profile 264

NUC-1031-Drug Profile 271

OGX-225-Drug Profile 273

oportuzumab monatox-Drug Profile 274

paclitaxel-Drug Profile 276

paclitaxel albumin bound-Drug Profile 278

paclitaxel albumin free-Drug Profile 281

patritumab-Drug Profile 282

pegargiminase-Drug Profile 284

pelareorep-Drug Profile 287

pembrolizumab-Drug Profile 292

QBECP-SSI-Drug Profile 300

rAd-IFN-Drug Profile 301

ramucirumab-Drug Profile 303

recMAGE-A3 + AS15-Drug Profile 309

Recombinant BCG-Pertussis Vaccine-Drug Profile 311

Recombinant Protein for Oncology and Infectious Disease-Drug Profile 312

RNAi Oligonucleotide to Inhibit TYRO-3 for Bladder Cancer-Drug Profile 313

S-588410-Drug Profile 314

sacituzumab govitecan-Drug Profile 315

sapanisertib-Drug Profile 316

SAR-408701-Drug Profile 318

SGT-94-Drug Profile 319

sirolimus albumin-bound-Drug Profile 320

SL-052-Drug Profile 322

SL-601-Drug Profile 324

Small molecule for Bladder Cancer-Drug Profile 325

Small Molecule to Antagonize GPR87 for Cancer-Drug Profile 326

Small Molecule to Inhibit TDO-2 for Cancer-Drug Profile 327

Small Molecule to Inhibit TYRO3 for Bladder Cancer-Drug Profile 328

Small Molecules to Activate Caspase 3 and Caspase 9 for Bladder and Urinary Tract Cancer-Drug Profile 329

Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis-Drug Profile 330

STA-128666-Drug Profile 331

sunitinib malate-Drug Profile 333

suramin hexasodium-Drug Profile 337

SVX-1-Drug Profile 339

SX-MTR1-Drug Profile 340

TD-210-Drug Profile 341

temsirolimus-Drug Profile 342

TF-011 Monomethyl Auristatin E-Drug Profile 344

TG-6002-Drug Profile 345

THR-53-Drug Profile 346

TMX-202-Drug Profile 347

TP-3654-Drug Profile 348

TT-16-Drug Profile 349

Urocidin-Drug Profile 350

Vaccine for Bladder Cancer-Drug Profile 352

Vaccine to Target NY-ESO-1 for Oncology-Drug Profile 353

vemurafenib-Drug Profile 354

vesigenurtucel-L-Drug Profile 357

VPM-1002-Drug Profile 358

Bladder Cancer-Recent Pipeline Updates 360

Bladder Cancer-Dormant Projects 482

Bladder Cancer-Discontinued Products 488

Bladder Cancer-Product Development Milestones 489

Featured News & Press Releases 489

Appendix 498

Methodology 498

Coverage 498

Secondary Research 498

Primary Research 498

Expert Panel Validation 498

Contact Us 498

Disclaimer 499

List of Tables

Number of Products under Development for Bladder Cancer, H2 2015 23

Number of Products under Development for Bladder Cancer-Comparative Analysis, H2 2015 24

Number of Products under Development by Companies, H2 2015 26

Number of Products under Development by Companies, H2 2015 (Contd..1) 27

Number of Products under Development by Companies, H2 2015 (Contd..2) 28

Number of Products under Development by Companies, H2 2015 (Contd..3) 29

Number of Products under Development by Companies, H2 2015 (Contd..4) 30

Number of Products under Development by Companies, H2 2015 (Contd..5) 31

Number of Products under Investigation by Universities/Institutes, H2 2015 34

Comparative Analysis by Late Stage Development, H2 2015 35

Comparative Analysis by Clinical Stage Development, H2 2015 36

Comparative Analysis by Early Stage Development, H2 2015 37

Products under Development by Companies, H2 2015 38

Products under Development by Companies, H2 2015 (Contd..1) 39

Products under Development by Companies, H2 2015 (Contd..2) 40

Products under Development by Companies, H2 2015 (Contd..3) 41

Products under Development by Companies, H2 2015 (Contd..4) 42

Products under Development by Companies, H2 2015 (Contd..5) 43

Products under Development by Companies, H2 2015 (Contd..6) 44

Products under Development by Companies, H2 2015 (Contd..7) 45

Products under Investigation by Universities/Institutes, H2 2015 46

Bladder Cancer-Pipeline by Advaxis, Inc., H2 2015 47

Bladder Cancer-Pipeline by Alligator Bioscience AB, H2 2015 48

Bladder Cancer-Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015 49

Bladder Cancer-Pipeline by Altor BioScience Corporation, H2 2015 50

Bladder Cancer-Pipeline by AndroScience Corporation, H2 2015 51

Bladder Cancer-Pipeline by APIM Therapeutics AS, H2 2015 52

Bladder Cancer-Pipeline by Arno Therapeutics, Inc., H2 2015 53

Bladder Cancer-Pipeline by Ascenta Therapeutics, Inc., H2 2015 54

Bladder Cancer-Pipeline by Astellas Pharma Inc., H2 2015 55

Bladder Cancer-Pipeline by AstraZeneca Plc, H2 2015 56

Bladder Cancer-Pipeline by AuraSense Therapeutics, LLC, H2 2015 57

Bladder Cancer-Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 58

Bladder Cancer-Pipeline by AvidBiotics Corp., H2 2015 59

Bladder Cancer-Pipeline by Bavarian Nordic A/S, H2 2015 60

Bladder Cancer-Pipeline by Bayer AG, H2 2015 61

Bladder Cancer-Pipeline by BioCancell Ltd, H2 2015 62

Bladder Cancer-Pipeline by Bioncotech Therapeutics S.L., H2 2015 63

Bladder Cancer-Pipeline by Biotest AG, H2 2015 64

Bladder Cancer-Pipeline by cCAM Biotherapeutics Ltd., H2 2015 65

Bladder Cancer-Pipeline by Celgene Corporation, H2 2015 66

Bladder Cancer-Pipeline by Celldex Therapeutics, Inc., H2 2015 67

Bladder Cancer-Pipeline by Cold Genesys, Inc., H2 2015 68

Bladder Cancer-Pipeline by Daiichi Sankyo Company, Limited, H2 2015 69

Bladder Cancer-Pipeline by DormaTarg, Inc., H2 2015 70

Bladder Cancer-Pipeline by Eisai Co., Ltd., H2 2015 71

Bladder Cancer-Pipeline by Eli Lilly and Company, H2 2015 72

Bladder Cancer-Pipeline by EntreChem, S.L., H2 2015 73

Bladder Cancer-Pipeline by Esperance Pharmaceuticals, Inc., H2 2015 74

Bladder Cancer-Pipeline by Evotec AG, H2 2015 75

Bladder Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 76

Bladder Cancer-Pipeline by Gene Signal International SA, H2 2015 77

Bladder Cancer-Pipeline by Genmab A/S, H2 2015 78

Bladder Cancer-Pipeline by GlaxoSmithKline Plc, H2 2015 79

Bladder Cancer-Pipeline by Heat Biologics, Inc., H2 2015 80

Bladder Cancer-Pipeline by Horizon Pharma Plc, H2 2015 81

Bladder Cancer-Pipeline by Hutchison MediPharma Limited, H2 2015 82

Bladder Cancer-Pipeline by Idera Pharmaceuticals, Inc., H2 2015 83

Bladder Cancer-Pipeline by Immunomedics, Inc., H2 2015 84

Bladder Cancer-Pipeline by Immupharma Plc, H2 2015 85

Bladder Cancer-Pipeline by ImmuRx, Inc., H2 2015 86

Bladder Cancer-Pipeline by Ludwig Institute For Cancer Research Ltd, H2 2015 87

Bladder Cancer-Pipeline by MacroGenics, Inc., H2 2015 88

Bladder Cancer-Pipeline by Marina Biotech, Inc., H2 2015 89

Bladder Cancer-Pipeline by Meabco A/S, H2 2015 90

Bladder Cancer-Pipeline by MedImmune, LLC, H2 2015 91

Bladder Cancer-Pipeline by Merck & Co., Inc., H2 2015 92

Bladder Cancer-Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 93

Bladder Cancer-Pipeline by Mirati Therapeutics Inc., H2 2015 94

Bladder Cancer-Pipeline by NuCana BioMed Limited, H2 2015 95

Bladder Cancer-Pipeline by Omeros Corporation, H2 2015 96

Bladder Cancer-Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2015 97

Bladder Cancer-Pipeline by Oncolytics Biotech Inc., H2 2015 98

Bladder Cancer-Pipeline by Oncopeptides AB, H2 2015 99

Bladder Cancer-Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 100

Bladder Cancer-Pipeline by Optimum Therapeutics, LLC, H2 2015 101

Bladder Cancer-Pipeline by Panacela Labs, Inc., H2 2015 102

Bladder Cancer-Pipeline by Pfizer Inc., H2 2015 103

Bladder Cancer-Pipeline by Pharma Mar, S.A., H2 2015 104

Bladder Cancer-Pipeline by Polaris Pharmaceuticals, Inc., H2 2015 105

Bladder Cancer-Pipeline by PsiOxus Therapeutics Limited, H2 2015 106

Bladder Cancer-Pipeline by Qu Biologics Inc., H2 2015 107

Bladder Cancer-Pipeline by Quest PharmaTech Inc., H2 2015 108

Bladder Cancer-Pipeline by Samyang Holdings Corporation, H2 2015 109

Bladder Cancer-Pipeline by Sanofi, H2 2015 110

Bladder Cancer-Pipeline by Serometrix, LLC, H2 2015 111

Bladder Cancer-Pipeline by Shionogi & Co., Ltd., H2 2015 112

Bladder Cancer-Pipeline by Sorrento Therapeutics, Inc., H2 2015 113

Bladder Cancer-Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015 114

Bladder Cancer-Pipeline by Stemline Therapeutics, Inc., H2 2015 115

Bladder Cancer-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 116

Bladder Cancer-Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015 117

Bladder Cancer-Pipeline by Synta Pharmaceuticals Corp., H2 2015 118

Bladder Cancer-Pipeline by TARIS BioMedical, Inc., H2 2015 119

Bladder Cancer-Pipeline by Telesta Therapeutics Inc., H2 2015 120

Bladder Cancer-Pipeline by Telormedix SA, H2 2015 121

Bladder Cancer-Pipeline by Theravectys SA, H2 2015 122

Bladder Cancer-Pipeline by TheRyte Limited, H2 2015 123

Bladder Cancer-Pipeline by Tolero Pharmaceuticals, Inc., H2 2015 124

Bladder Cancer-Pipeline by Transgene SA, H2 2015 125

Bladder Cancer-Pipeline by Vakzine Projekt Management GmbH, H2 2015 126

Bladder Cancer-Pipeline by Vaxeal Holding SA, H2 2015 127

Bladder Cancer-Pipeline by Viralytics Ltd., H2 2015 128

Bladder Cancer-Pipeline by Viventia Biotechnologies Inc., H2 2015 129

Assessment by Monotherapy Products, H2 2015 130

Assessment by Combination Products, H2 2015 131

Number of Products by Stage and Target, H2 2015 133

Number of Products by Stage and Mechanism of Action, H2 2015 138

Number of Products by Stage and Route of Administration, H2 2015 142

Number of Products by Stage and Molecule Type, H2 2015 144

Bladder Cancer Therapeutics-Recent Pipeline Updates, H2 2015 369

Bladder Cancer-Dormant Projects, H2 2015 491

Bladder Cancer-Dormant Projects (Contd..1), H2 2015 492

Bladder Cancer-Dormant Projects (Contd..2), H2 2015 493

Bladder Cancer-Dormant Projects (Contd..3), H2 2015 494

Bladder Cancer-Dormant Projects (Contd..4), H2 2015 495

Bladder Cancer-Dormant Projects (Contd..5), H2 2015 496

Bladder Cancer-Discontinued Products, H2 2015 497

List of Figures

Number of Products under Development for Bladder Cancer, H2 2015 23

Number of Products under Development for Bladder Cancer-Comparative Analysis, H2 2015 24

Number of Products under Development by Companies, H2 2015 25

Number of Products under Investigation by Universities/Institutes, H2 2015 33

Comparative Analysis by Late Stage Development, H2 2015 35

Comparative Analysis by Clinical Stage Development, H2 2015 36

Comparative Analysis by Early Stage Products, H2 2015 37

Assessment by Monotherapy Products, H2 2015 130

Assessment by Combination Products, H2 2015 131

Number of Products by Top 10 Targets, H2 2015 132

Number of Products by Stage and Top 10 Targets, H2 2015 132

Number of Products by Top 10 Mechanism of Actions, H2 2015 137

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 137

Number of Products by Top 10 Routes of Administration, H2 2015 141

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 141

Number of Products by Top 10 Molecule Types, H2 2015 143

Number of Products by Stage and Top 10 Molecule Types, H2 2015 143

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Advaxis, Inc.

Alligator Bioscience AB

Alnylam Pharmaceuticals, Inc.

Altor BioScience Corporation

AndroScience Corporation

APIM Therapeutics AS

Arno Therapeutics, Inc.

Ascenta Therapeutics, Inc.

Astellas Pharma Inc.

AstraZeneca Plc

AuraSense Therapeutics, LLC

AVEO Pharmaceuticals, Inc.

AvidBiotics Corp.

Bavarian Nordic A/S

Bayer AG

BioCancell Ltd

Bioncotech Therapeutics S.L.

Biotest AG

cCAM Biotherapeutics Ltd.

Celgene Corporation

Celldex Therapeutics, Inc.

Cold Genesys, Inc.

Daiichi Sankyo Company, Limited

DormaTarg, Inc.

Eisai Co., Ltd.

Eli Lilly and Company

EntreChem, S.L.

Esperance Pharmaceuticals, Inc.

Evotec AG

F. Hoffmann-La Roche Ltd.

Gene Signal International SA

Genmab A/S

GlaxoSmithKline Plc

Heat Biologics, Inc.

Horizon Pharma Plc

Hutchison MediPharma Limited

Idera Pharmaceuticals, Inc.

Immunomedics, Inc.

Immupharma Plc

ImmuRx, Inc.

Ludwig Institute For Cancer Research Ltd

MacroGenics, Inc.

Marina Biotech, Inc.

Meabco A/S

MedImmune, LLC

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

Mirati Therapeutics Inc.

NuCana BioMed Limited

Omeros Corporation

Oncogenex Pharmaceuticals, Inc.

Oncolytics Biotech Inc.

Oncopeptides AB

Ono Pharmaceutical Co., Ltd.

Optimum Therapeutics, LLC

Panacela Labs, Inc.

Pfizer Inc.

Pharma Mar, S.A.

Polaris Pharmaceuticals, Inc.

PsiOxus Therapeutics Limited

Qu Biologics Inc.

Quest PharmaTech Inc.

Samyang Holdings Corporation


Serometrix, LLC

Shionogi & Co., Ltd.

Sorrento Therapeutics, Inc.

Spectrum Pharmaceuticals, Inc.

Stemline Therapeutics, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Sun Pharma Advanced Research Company Ltd.

Synta Pharmaceuticals Corp.

TARIS BioMedical, Inc.

Telesta Therapeutics Inc.

Telormedix SA

Theravectys SA

TheRyte Limited

Tolero Pharmaceuticals, Inc.

Transgene SA

Vakzine Projekt Management GmbH

Vaxeal Holding SA

Viralytics Ltd.

Viventia Biotechnologies Inc.

Bladder Cancer Therapeutic Products under Development, Key Players in Bladder Cancer Therapeutics, Bladder Cancer Pipeline Overview, Bladder Cancer Pipeline, Bladder Cancer Pipeline Assessment

select a license

Single User License
USD 2000 INR 128780
Site License
USD 4000 INR 257560
Corporate User License
USD 6000 INR 386340



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@]